GlaxoSmithKline (GSK) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $103.60B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | GB | CEO | Luke Victor Miels |
| IPO Date | 1980-03-28 | CAGR | 8.35% |
| Employees | 66,841 | Website | www.gsk.com |
| Div. Yield | 2.62% | Payout Ratio | 45% |
| Buy Back Yield | 0.95% | Total Yield | 3.57% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $104.80B | P/E | 11.09 | Forward P/E | 9.95 | PEG | 1.61 |
| P/S | 3.1 | P/B | 5.78 | P/CF | 13.61 | P/FCF | 20.33 |
| Sales | $44.03B | Sales 1Y | 3.97% | Sales 3Y | 12.7% | Sales 5Y | 1.09% |
| EPS | $4.63 | EPS 1Y | 122.22% | EPS 3Y | 48.67% | EPS 5Y | 28.24% |
| Sales QoQ | -11.48% | EPS QoQ | 4.88% | Sales QoQ Avg | 0.66% | EPS QoQ Avg | 4.57% |
| Gross Margin | 72.74% | Operating Margin | 22.34% | Profit Margin | 17.78% | ROCE | 18.11% |
| ROA | 9% | ROE | 36% | Altman Z Score | 1.66 | Piotroski Score | 7 |
| Current Ratio | 0.79 | Quick Ratio | 0.52 | Cash Ratio | 0.15 | Op. CF Ratio | 0.04 |
| Debt/Equity | 1.07 | Debt/Assets | 0.3 | Lt Debt/Equity | 0.78 | Lt Debt/Cap. | 0.44 |
| Intrst Cov. | 10.37 | Inventory Turnover | 1.45 | Asset Turnover | 0.52 | Receivables Turnover | 4.23 |
| Enterprise Value | $104.80B | P/E Ratio | 11.09 |
| Forward P/E | 9.95 | PEG Ratio | 1.61 |
| P/S Ratio | 3.1 | P/B Ratio | 5.78 |
| P/CF Ratio | 13.61 | P/FCF Ratio | 20.33 |
| EPS | $4.63 | EPS Growth 1Y | 122.22% |
| EPS Growth 3Y | 48.67% | EPS Growth 5Y | 28.24% |
| Revenue Growth 1Y | 3.97% | Gross Margin | 0.73% |
| Operating Margin | 0.22% | Profit Margin | 0.18% |
| ROE | 0.36% | ROA | 0.09% |
| ROCE | 0.18% | Current Ratio | 0.79 |
| Quick Ratio | 0.52 | Cash Ratio | 0.15 |
| Debt/Equity | 1.07 | Interest Coverage | 10.37 |
| Altman Z Score | 1.66 | Piotroski Score | 7 |
GlaxoSmithKline (GSK) valuation & financials
GlaxoSmithKline (GSK) has a market capitalization of $103.60B and trades at a price-to-earnings ratio of 11.1. It operates in the Healthcare sector (Drug Manufacturers - General).
GlaxoSmithKline's revenue grew +4.0% over the last year.
GlaxoSmithKline's next earnings report is scheduled for July 28, 2026 before market open; analysts estimate EPS of $1.27.
GlaxoSmithKline (GSK) — frequently asked questions
When does GlaxoSmithKline (GSK) report earnings next?
GlaxoSmithKline is expected to report earnings on July 28, 2026 before market open. Analysts estimate EPS of $1.27.
What is GlaxoSmithKline's market cap?
GlaxoSmithKline (GSK) has a market capitalization of $103.60B.
What is GSK's P/E ratio?
GlaxoSmithKline trades at a price-to-earnings ratio of 11.1, with trailing twelve-month EPS of $4.63.
How fast is GlaxoSmithKline growing?
GlaxoSmithKline's revenue grew +4.0% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)